Clinical Rheumatology

, Volume 29, Issue 3, pp 315–323 | Cite as

Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus

  • Wen-Xian Li
  • Hai-Feng Pan
  • Jian-Li Hu
  • Chang-Zhong Wang
  • Ning Zhang
  • Jing Li
  • Xiang-Pei Li
  • Jian-Hua Xu
  • Dong-Qing Ye
Brief Report

Abstract

This study aims to explore the percentage of T-cell and NK-cell subsets, the expression of NKG2A and NKG2D on CD3+ T cells and CD3−CD56+ NK cells on the total lymphocytes in new-onset systemic lupus erythematosus (SLE) patients, and explore clinical significance of these cell subsets. Thirty-two SLE patients and 32 normal controls were enrolled. Flow cytometry was used to count T- and NK-cell subsets and to detect the expression of NKG2A and NKG2D on CD3+ T cells and CD3−CD56+ NK cells in patients with new-onset SLE. Results show that CD4+ T (t = 2.04, P < 0.05), CD4+/CD8+ T cell (t = 2.66, P < 0.05), CD4+ CD25+ T (t = 2.48, P < 0.05), CD3+CD56+ natural killer T (NKT) (t = 40.05, P < 0.01), CD3−CD56+CD16+ NK-cell subsets (t = 3.50, P < 0.01) were significantly decreased, CD8+ T-cell subsets was significantly increased in patients with new-onset SLE (t = 3.80, P < 0.01), as compared with healthy controls. CD8+ T-cell subset was significantly increased in patients with vasculitis (t = 2.47, P < 0.05), and CD3−CD56+CD16+ NK was increased in patients with arthritis (t = 3.21, P < 0.01). However, no statistically significant correlation was found among different PBMC subsets and SLEDAI activity scores. Patients with SLE had a lower expression of NKG2A (U = 2.42, P < 0.05) as well as NKG2A/NKG2D ratio (t = 2.61, P < 0.05) and a higher expression of NKG2D (t = 2.21, P < 0.05) on CD3+ T cells, compared with normal controls. However, they had a higher expression of NKG2A (t = 2.59, P < 0.05) as well as NKG2A/NKG2D ratio (t = 49.45, P < 0.01) and a lower expression of NKG2D (t = 3.05, P < 0.01) on CD3−CD56+ NK cells. Taken together, the findings indicate the decreased CD4+ T-cell, CD4+/CD8+ T-cell, CD4+CD25+ T-cell, CD3+CD56+ NKT-, and CD3−CD56+CD16+ NK-cell subsets, increased CD8+ T-cell subsets as well as the abnormal expression of NKG2A and NKG2D on CD3+ T and CD3−CD56 + NK cells may play a role in the etiology of SLE.

Keywords

NK-cell subset NKG2A NKG2D Systemic lupus erythematosus T-cell subset 

Introduction

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, characterized by a multitude of autoantibody production, complement activation and immune-complex deposition, causing tissue and organ damage [1]. At present, the pathogenesis of SLE remains unclear. However, there is a large body of evidence that immunological disturbances play a key role in the pathogenesis of SLE [2, 3, 4]. It would be interesting to highlight the influence of autoantibodies on the immunological status of patients with SLE including leuko-/lymphocytopenia. Immunological characteristics of SLE are hyperactive B cells and abnormal T cells, which lead to the production of autoantibodies against components of the cell nucleus. It is generally accepted that T and B lymphocytes play key roles at multiple stages in the onset and progression of SLE. Recently, a possible role of natural killer (NK) cells in the pathogenesis of SLE has been suggested [5, 6, 7], which are lymphocytes belonging to the innate immune system, playing an important role in innate immunity and adaptive immunity [8]. However, the current studies about the amount of T-cell subsets and NK-cell subsets in SLE are in disagreement.

More than ten NK cell receptors have been discovered so far [9], among which, NKG2A is inhibitory while NKG2D is activating. Adverse regulative signals are transmitted by NKG2A and NKG2D. Normally, the expression of NKG2A and NKG2D incline to balance. Patients with SLE have low numbers of NK cells in the peripheral blood [10, 11]. However, the role of NK cell receptors in SLE has been rarely studied. In the present study, we apply flow cytometry (FCM) to count T- and NK-cell subsets, and detect the expression of NKG2A/NKG2D on CD3+ T cells and CD3−CD56+ NK cells in patients with new-onset SLE.

Materials and methods

Patients

Thirty-two SLE patients (M/F = 2/30), fulfilling the ACR criteria [12], were included in the study, as well as 32 race-, gender- and age-matched healthy volunteers from the same geographical area.

The characteristics of the controls and patients are shown in Table 1. Each of the patients and controls gave an informed consent before being recruited into the study. New-onset SLE was defined by the following criteria: (1) first time diagnosis of SLE; (2) no history of corticosteroids or immunosuppressive drugs use before registration [11]. Renal involvement of SLE was defined according to the ACR criteria, i.e., any one of the following: (1) persistent proteinuria ≥0.5 g/day; (2) the presence of active cellular casts; or (3) biopsy evidence of lupus nephritis (LN)[12]. Normal controls have satisfied certain conditions. They didn’t meet the diagnostic standard of SLE, without history of major diseases and family history of autoimmune diseases (Table 1).
Table 1

Characteristics of controls and patients with systemic lupus erythematosus

Characteristics

Controls (n = 32)

SLE patients (n = 32)

Male/female

2/30

2/30

Age (Mean±SD)

29.74 ± 12.20

32.97 ± 13.20

SLEDAI (median and range)

 

13 (5–30)

New rash

 

50%

Renal disease

 

34.38%

Arthritis

 

75%

Vasculitis

 

15.63%

Anti-dsDNA+

 

65.63%

Low complement

 

75%

The baseline demographic and clinical data were collected from hospital records and reviewed by experienced physicians. The data included age, gender, and medication. Disease activity was determined by calculating the SLE disease activity index (SLEDAI) [13]. Routine laboratory investigation included full blood count; erythrocyte sedimentation rate; serum levels of C-reactive protein; serum concentrations of complement factors C3 and C4; anti-dsDNA using an immunoblotting technique; serum IgG, IgM, and IgA; and 24-h urinary protein levels.

Flow cytometry

Blood samples from all subjects were stained and analyzed within 6 h of the collection. A whole blood lysing method, using monoclonal antibodies that had been directly conjugated to fluorescein (FITC), phycoerythrin (PE), and Cy-chrome (Cy), was carried out to stain white blood cells. Lymphocyte subset analyses of patients and of normal controls were performed by direct three-color immunofluorescence and flow cytometry (FACScalibur, BD, USA).

Mouse IgG1 monoclonal antibodies with appropriate isotype controls were obtained as follows: anti-human CD3(Cy5), anti-human FITC-CD56, anti-human FITC-CD4, anti-human PE-CD4 , anti-human PE-CD8, anti-human FITC-CD25 (BD Pharmingen Company, USA), anti-human PE-NKG2A, and anti-human PE-NKG2D (R&D System Company, USA).

Winmdi 2.9 software was used to obtain percentages of lymphocyte subsets. For each sample, a lymphocyte gate was set on the basis of linear forward and side scatter. NK cells were defined as CD3−CD56+ lymphocytes while T cells were the CD3+ populations.

Statistical analyses

All statistical analyses were performed by SPSS 10.01 (SPSS Inc., Chicago, IL, USA). Test of the normal distribution of the data was made using the Kolmogorow–Smirnow test. If the data were normally distributed, it was described as mean ± SD. Otherwise, it was described as median and P25 ∼ P75. The significance of the results was analyzed by Student's t test or the Mann–Whitney U test. Probability level less than 0.05 were used as a criterion of significance.

Result

The percentages of T cells and NK Cells in total lymphocytes

The percentage of CD4+ T cells were lower in SLE patients than in controls (t = 2.04, P < 0.05), while CD8+ elements were higher in frequency (t = 3.80, P < 0.01). The CD4+/CD8+ ratio was significantly lower in SLE patients (t = 2.66, P < 0.05). As shown in Table 2, with respect to controls, SLE patients had considerably decreased values of CD4+CD25+ T cells (t = 2.48, P < 0.05), CD3+CD56+ natural killer T (NKT) cells (t = 40.05, P < 0.01), and CD3−CD56+CD16+ NK cells (t = 3.50, P < 0.01).
Table 2

The percentages of T cells and NK cells in total lymphocytes in patients and controls

 

SLE patients

controls

t value

P value

 

(n = 32)

(n = 32)

CD3+ T cells

72.79% ± 10.57%

69.94% ± 7.79%

1.23

>0.05

CD4+ T cells

35.87% ± 9.91%

40.28% ± 7.14%

2.04

<0.05

CD8+ T cells

33.59% ± 11.62%

24.30% ± 7.53%

3.80

<0.01

CD4+/CD8+ ratio

1.31% ± 0.85%

1.85% ± 0.78%

2.66

<0.05

CD4+CD25+ T cells

3.99% ± 1.57%

5.38% ± 2.76%

2.48

<0.05

CD3+CD56+ NKT cells

2.40% ± 1.51%

5.12% ± 3.92%

40.05

<0.01

CD3−CD56+CD16-NK cells

0.78% ± 0.54%

0.93% ± 0.64%

0.98

>0.05

CD3−CD56+D16+ NK cells

5.86% ± 4.77%

10.99% ± 6.79%

3.50

<0.01

CD3−CD56−CD16+ NK cells

1.36% ± 0.90%

1.58% ± 0.97%

0.96

>0.05

No statistically significant correlation was found among different PBMC subsets and SLEDAI activity scores.

When major clinical characteristics were considered, we found that there was a significant difference in CD8+ T cells between patients with and without vasculitis (44.53% ± 14.58%, n = 5; 31.58% ± 10.05%, n = 27; t = 2.47, P < 0.05). Similarly, we observed a significant difference in CD3−CD56+CD16+ NK cells between patients with and without arthritis (6.87% ± 5.02%, n = 24; 2.68% ± 2.03%, n = 8; t = 3.21, P < 0.01). However, different PBMC subsets did not differ between patients with and without fever, nor was any difference found when different T- and NK-cell subsets were compared between patients with and without rash, alopecia, mucosal ulcers, pleurisy, pericarditis, myositis, and nephritis.

The expression of NKG2A and NKG2D on T and NK cells

The expression of NKG2A on CD3+ T cells in SLE patients (3.12% ± 2.61%, n = 32) was significantly decreased than that of healthy controls (median = 3.78%, P25 ∼ P75 = 2.30% ∼ 7.00%, n = 32; Mann–Whitney U test, P < 0.05), shown in Fig. 1. However, the expression of NKG2D on CD3+ T cells in SLE patients (49.47% ± 12.91%, n = 32) was significantly increased than that of healthy controls (43.65% ± 7.43%, n = 32), shown in Fig. 2.
Fig. 1

The expression of NKG2A on CD3+ T cells in patients and controls. Shown are the NKG2A positive rates on CD3+ T lymphocytes in healthy controls and patients with SLE (a) and the typical two-dimensional scatter diagram about the expression of NKG2A on CD3+ T lymphocytes of healthy controls (b) and of patients with SLE (c)

Fig. 2

The expression of NKG2D on CD3+ T cells in patients and controls. Shown are the NKG2D positive rates on CD3+ T lymphocytes in healthy controls and patients with SLE (a) and the typical two-dimensional scatter diagram about the expression of NKG2D on CD3+ T lymphocytes of healthy controls (b) and of patients with SLE (c)

The expression of NKG2A on CD3−CD56+ NK cells in SLE patients (23.36% ± 16.37%, n = 32) was significantly increased than that of healthy controls (14.60% ± 9.88%, n = 32), shown in Fig. 3. However, the expression of NKG2D on CD3−CD56+ NK cells in SLE patients (86.36% ± 11.83%, n = 32) was significantly decreased than that of healthy controls (93.13% ± 4.20%, n = 32), shown in Fig. 4.
Fig. 3

The expression of NKG2A on CD3−CD56+ NK cells in patients and controls. Shown are the NKG2A positive rates on CD3−CD56+ NK cells in healthy controls and patients with SLE (a) and the typical two-dimensional scatter diagram about the expression of NKG2A on CD3−CD56+ NK cells of healthy controls (b) and of patients with SLE (c)

Fig. 4

The expression of NKG2D on CD3−CD56+ NK cells in patients and controls. Shown are the NKG2D positive rates on CD3−CD56+ NK cells in healthy controls and patients with SLE (a) and the typical two-dimensional scatter diagram about the expression of NKG2D on CD3−CD56+ NK cells of healthy controls (b) and of patients with SLE (c)

Tables 3 and 4 showed the prevalence of NKG2A and NKG2D as well as NKG2A/NKG2D ratio on CD3+ T cells and CD3−CD56+ NK cells, respectively.
Table 3

The prevalence of NKG2A and NKG2D on CD3+ T cells in patients and controls

 

NKG2A

NKG2D

NKG2A/NKG2D

SLE patients(n = 32)

3.12 ± 2.61

49.47 ± 12.91

6.65 ± 6.08

Controls(n = 32)

2.30–7.00 (3.78)

43.65 ± 7.43

11.69 ± 9.06

t/U

2.42

2.21

2.61

P

<0.05

<0.05

<0.05

Table 4

The prevelance of NKG2A and NKG2D on CD3−CD56+ NK cells in patients and controls

 

NKG2A

NKG2D

NKG2A/NKG2D

SLE patients(n = 32)

23.36 ± 16.37

86.36 ± 11.83

27.12 ± 18.21

Controls(n = 32)

14.60 ± 9.88

93.13 ± 4.20

15.63 ± 10.46

t

2.59

3.05

49.45

P

<0.05

<0.01

<0.01

Discussion

In SLE, the most common changes in T- and NK-cell subsets are a reduction of CD4+ T cells and an elevation of CD8+ T cells with imbalance of CD4+/CD8+ ratio [14]. Spinozzi et al. [15] reported that CD8+ T cells in SLE patients was mostly made up of γδT cell subpopulation, a kind of contrasuppressor T lymphocytes, which cannot suppress but help CD4+ T cells activation. γδT cell subpopulation disappeared and clinical and pathological remission SLE was often obtained after in vivo immunosuppressive therapy. Jiang et al. [16] pointed out that patients with active SLE had a markedly low percentage of T4+2H4+ cells, which cannot induce CD8+ T to inhibit B cells. Therefore, a reduction of CD4+ T cells and an elevation of CD8+ T cells in SLE still lead to B hyperactivity.

Recent studies have suggested that CD4+CD25+ T cells, also called regulatory T cells, exhibit immune suppressive activity and also play a critical role in the maintenance of self-tolerance [17, 18, 19, 20]. Some studies concerning the role of CD4+CD25+ T cells in lupus revealed decreased frequencies of these cells in SLE patients [21, 22, 23] and lupus mice [24]. Similar results had been observed in our research.

NKT cells are a subset of T cells that share properties of natural killer cells and conventional T cells. NKT cells are involved in a number of pathological conditions and have been implicated in the pathogenesis of autoimmune diseases [25]. In our study, NKT cells were decreased in SLE patients than in controls, which was similar to previous studies [26, 27].

NK cells were once regarded as effector cells of natural immunity. However, they are now revealing themselves as multifunctional regulatory cells that are present throughout the body. The role of NK cells in autoimmunity is attracting increased attention, although the picture is clouded by a broad range of data that presents disease-promoting [28] as well as disease-protective roles [29]. Our results further verify that patients with SLE have low numbers of NK cells circulating in the blood, which were in accordance with previous reports[10, 11]. Genetic factors [7] and apoptosis [30] are related to NK cell deficiency.

This study found out that the association of different T- and NK-cell subsets and SLEDAI activity scores was not statistically significant. There were few studies to data discussing the correlation. We suppose that the pathogenesis of SLE is complicated, and different clinical subtypes and individuals have the different immune disorder. Moreover, various cell subsets mutually stimulate and/or inhibit under the different immune state. Therefore, the percentage of only one kind of T- and NK-cell subsets in total lymphocytes does not represent SLEDAI activity scores.

Our study found that patients with vasculitis have an increased CD8+ T-cell percentage, and patients with arthritis have an increased CD3−CD56+CD16+ NK-cell percentage. Vasculitis is inflammation of blood vessels and may affect both arteries and veins, which is diagnosed primarily by history and clinical examination. There were few studies to data discussing the relationship between clinical characteristics and PBMC subsets. The result indicates CD8+ T and CD3−CD56+CD16+ NK cells may serve as a predictor of inflammation in SLE.

The term “NK cell receptors” is used to describe the growing number of activating and inhibitory cell-surface receptors known to be expressed by NK cells, while in some cases also expressed by other immune cell. NKG2A, NKG2C, and NKG2E are highly homologous lectin-like NK cell receptors that form heterodimers with the CD94 molecule [31]. NKG2A, containing immunoreceptor tyrosine-based inhibition motif, is inhibitory, whereas the others are stimulatory. These receptors recognize peptides derived from the leader sequence of many classical MHC class I molecules, embedded in the groove of a specialized non-classical class I molecule called HLA-E (in humans) or Qa-1 (in mice) [32]. NKG2D, belonging to C-type lectin containing immunoreceptor tyrosine-based activation motif, which is activating, shares little sequence homology with the NKG2 receptor family members, and does not appear to pair with CD94 [31]. Unlike the activating members of the Ly49 and NKG2 families, NKG2D uses DAP10, rather than DAP12, as an adapter signaling molecule [33]. Interestingly, the diverse ligands recognized by NKG2D include multiple members of at least two gene families, all of which are only distantly related to MHC class I molecules. Patients with SLE have low numbers of NK cells circulating in the blood [10, 11]. However, the role of NK cell receptors in SLE has been rarely studied. We have attempted to answer this question by determining NKG2A/NKG2D expression on CD3+ T lymphocytes and CD3−CD56+ NK cells in patients with SLE, which is the novel aspect of the study. What is more, we recruited patients with new-onset SLE in order to eliminate the treatment and medicine influence on results.

In this study, we found that the expression of NKG2A on CD3+ T cells in SLE patients was significantly decreased, while NKG2D was significantly increased. It was reported that [34] NKG2A resists NK as well as CTL-mediated lysis in vitro, while NKG2D functioned as a costimulatory receptor in the adaptive immune system (CD8+ T cells) or as both a primary recognition structure and a costimulatory receptor in the innate immune system (NK cells and macrophages) [35]. Our results, together with those from previous studies indicated that the abnormal expression of NKG2A and NKG2D on CD3+ T cells may participate in the pathogenesis of SLE. The cytolytic activity and cytokine production of NK cells is tightly regulated by an array of activating and inhibitory receptors on the cell surface [36]. Our detecting results of NKG2A and NKG2D on NK cells confirmed several groups' reports, which pointed out that the functional activity of NK cells was diminished in SLE [7, 37].

Conclusion

To summarize, our findings indicate that the decreased CD4+/CD8+ T cell, CD4+ T, CD4+CD25+ T-, NKT-, and NK-cell subsets, increased CD8+ T-cell subsets, as well as altered expression of NKG2A and NKG2D on CD3+ T and CD3−CD56+ NK cells may play an important role in the regulation of NK cell activities and pathogenesis of SLE.

Notes

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (30771848) and the key program of National Natural Science Foundation of China (30830089).

Disclosures

None.

References

  1. 1.
    Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939CrossRefPubMedGoogle Scholar
  2. 2.
    Böhm I (2006) Quantification of absolute peripheral white blood cells and their subsets in patients with lupus erythematosus: comparison with other inflammatory diseases with and without autoimmune background. Biomed Pharmacother 60:92–95CrossRefPubMedGoogle Scholar
  3. 3.
    Böhm I (2005) Nuclear-targeting autoantibodies induced nuclear PARP cleavage accompanied by more pronounced decrease of peripheral white blood cells than Ro/SSA and La/SSB antigen-targeting autoantibodies. J Clin Immunol 25:99–105CrossRefPubMedGoogle Scholar
  4. 4.
    Böhm I (2004) Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 33(6):409–416CrossRefPubMedGoogle Scholar
  5. 5.
    Park YW, Kee SJ, Cho YN et al (2009) Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 60:1753–1763CrossRefPubMedGoogle Scholar
  6. 6.
    Schepis D, Gunnarsson I, Eloranta ML et al (2009) Increased proportion of CD56 bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126:140–146CrossRefPubMedGoogle Scholar
  7. 7.
    Green MR, Kennell AS, Larche MJ et al (2005) Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 141:165–173CrossRefPubMedGoogle Scholar
  8. 8.
    Johansson S, Berg L, Hall H et al (2005) NK cells: elusive players in autoimmunity. Trends Immunol 26:613–618CrossRefPubMedGoogle Scholar
  9. 9.
    Middleton D, CurranM ML (2002) Natural killer cells and their receptors. Transpl Immunol 10:147–164CrossRefPubMedGoogle Scholar
  10. 10.
    Yabuhara A, Yang FC, Nakazawa T et al (1996) A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 23:171–177PubMedGoogle Scholar
  11. 11.
    Erkeller-Yüsel F, Hulstaart F, Hannet I et al (1993) Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 2:227–231PubMedGoogle Scholar
  12. 12.
    Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
  13. 13.
    Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640CrossRefPubMedGoogle Scholar
  14. 14.
    Bakke AC, Kirkland PA, Kitridou RC et al (1983) T lymphocyte subsets in systemic lupus erythematosus. Correlations with corticosteroid therapy and disease activity. Arthritis Rheum 26:745–750CrossRefPubMedGoogle Scholar
  15. 15.
    Spinozzi F, Agea E, Bistoni O et al (1995) T lymphocytes bearing the gamma delta T cell receptor are susceptible to steroid-induced programmed cell death. Scand J Immunol 41:504–508CrossRefPubMedGoogle Scholar
  16. 16.
    Jiang M, Sun HY, Zu LP (1991) Studies on the T4 + 2H4+ cell of peripheral blood lymphocyte in systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 30(426–8):57Google Scholar
  17. 17.
    Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389–400PubMedGoogle Scholar
  18. 18.
    Takahashi T, Kuniyasu Y, Toda M et al (1998) Immunologic self-tolerance maintained by CD25 + CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10:1969–1980CrossRefPubMedGoogle Scholar
  19. 19.
    Itoh M, Takahashi T, Sakaguchi N et al (1999) Thymus and autoimmunity: production of CD25 + CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317–5326PubMedGoogle Scholar
  20. 20.
    Kuniyasu Y, Takahashi T, Itoh M et al (2000) Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 12:1145–1155CrossRefPubMedGoogle Scholar
  21. 21.
    Crispin JC, Martinez A, Alcocer-Varela J (2003) Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21:273–276CrossRefPubMedGoogle Scholar
  22. 22.
    Liu MF, Wang CR, Fung LL et al (2004) Decreased CD4 + CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 59:198–202CrossRefPubMedGoogle Scholar
  23. 23.
    Lee JH, Wang LC, Lin YT et al (2006) Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117:280–286CrossRefPubMedGoogle Scholar
  24. 24.
    Wu HY, Staines NA (2004) A deficiency of CD4 + CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 13:192–200CrossRefPubMedGoogle Scholar
  25. 25.
    Mercer JC, Ragin MJ, August A (2005) Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 37:1337–1343CrossRefPubMedGoogle Scholar
  26. 26.
    Gapin L, Matsuda JL, Surh CD et al (2001) NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2:971–978CrossRefPubMedGoogle Scholar
  27. 27.
    van der Vliet HJ, von Blomberg BM, Nishi N et al (2001) Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100:144–148CrossRefPubMedGoogle Scholar
  28. 28.
    Shj FD, Wang HB, Li H et al (2000) Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 1:245–251CrossRefGoogle Scholar
  29. 29.
    Takahashi K, Aranami T, Endoh M et al (2004) The regulatory role of natural killer cells in multiple sclerosis. Brain 127:1917–1927CrossRefPubMedGoogle Scholar
  30. 30.
    Eneslätt K, Rantapää-Dahlqvist S, Uddhammar A et al (2001) The regulation of FasL expression—a distinquishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE. J Clin Immunol 21:183–192CrossRefPubMedGoogle Scholar
  31. 31.
    Lazetic S, Chang C, Houchins JP et al (1996) Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol 157:4741–4745PubMedGoogle Scholar
  32. 32.
    López-Botet M, Bellón T (1996) Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol 11:301–307CrossRefGoogle Scholar
  33. 33.
    Wu J, Song Y, Bakker AB et al (1996) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730–732CrossRefGoogle Scholar
  34. 34.
    Szekeres-Bartho J, Barakonyi A, Miko E et al (2001) The role of gamma/delta T cells in the feto-maternal relationship. Semin Immunol 13:229–233CrossRefPubMedGoogle Scholar
  35. 35.
    Diefenbach A, Tomasello E, Lucas M et al (2002) Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3:1142–1149CrossRefPubMedGoogle Scholar
  36. 36.
    Raulet DH, Vance RE, McMahon CW (2001) Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19:291–330CrossRefPubMedGoogle Scholar
  37. 37.
    Nilsson N, Carlsten H (1996) Enhanced natural but diminished antibody-mediated cytotoxicity in the lungs of MRLlpr/lpr mice. Clin Exp Immunol 105:480–485CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Wen-Xian Li
    • 1
  • Hai-Feng Pan
    • 1
  • Jian-Li Hu
    • 1
  • Chang-Zhong Wang
    • 1
    • 2
  • Ning Zhang
    • 1
  • Jing Li
    • 1
  • Xiang-Pei Li
    • 3
  • Jian-Hua Xu
    • 4
  • Dong-Qing Ye
    • 1
  1. 1.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityHefeiPeople’s Republic of China
  2. 2.Department of ImmunologyAnhui University of Traditional Chinese MedicineHefeiPeople’s Republic of China
  3. 3.Department of RheumatologyAnhui Provincial HospitalHefeiPeople’s Republic of China
  4. 4.Department of Rheumatology, First Affiliated HospitalAnhui Medical UniversityHefeiPeople’s Republic of China

Personalised recommendations